Antigenics Inc. (New York) Sells $25 Million Of Convertible Senior Secured Notes

NEW YORK--(BUSINESS WIRE)--Antigenics Inc. (NASDAQ: AGEN) announced today that it has executed a definitive agreement for the sale of $25 million of convertible senior notes (“Notes”) to a group of accredited investors (“Investors”). No brokerage or sales commission is associated with the transaction. At the Investors’ option, the Notes are convertible into Antigenics’ common stock at $3.50 per share, representing a 74-percent premium to yesterday’s closing price.

MORE ON THIS TOPIC